|
|
|
|
|
|
|
|
Clinical Cancer Research
Abstract
CA125
dominated performance for ovarian cancer early detection among four
serum biomarkers evaluated in EPIC study prediagnostic serum, rising on
average 3 years prior to detection. Adding HE4 provided only marginal
improvement. This natural history supports annual testing for early
detection and highlights the importance of biomarker discovery
complementing CA125. Clin Cancer Res; 22(18); 4542–4. ©2016 AACR.
See related article by Terry et al., p. 4664